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ABSTRACT 
Excessive alcohol consumption is one of the main causes of death and disability 
worldwide.  Alcohol consumption is a heritable complex trait.  We conducted a 
meta-analysis of genome-wide association studies (GWAS) of gram/day (g/d) alcohol 
consumption in UK-Biobank, AlcGen and CHARGE+ consortia accumulating 480,842 
people of European descent to decipher the genetic architecture of alcohol intake. 
We identified 46 novel, common loci, and investigated their potential functional 
significance using magnetic resonance imaging data and gene expression studies. 
Our results identify genetic pathways associated with alcohol consumption and 
suggest shared genetic mechanisms with neuropsychiatric disorders including 
schizophrenia. 
Excessive alcohol consumption is a major public health problem that is responsible 
for 2.2% and 6.8% age-standardized deaths for women and men respectively1. Most 
genetic studies of alcohol use focus on alcohol dependency, although the population 
burden of alcohol-related disease mainly reflects a broader range of alcohol 
consumption behaviors2. Small reductions in alcohol consumption could have major 
public health benefits; even moderate amounts of alcohol/day may have significant 
impact on mortality3. 
Alcohol consumption is a heritable complex trait4, but genetic studies to date have 
robustly identified only a small number of associated genetic variants 5-8. These 
include variants in the aldehyde dehydrogenase (ADH) gene family, a group of 
enzymes that catalyze the oxidation of aldehydes9, including a cluster of genes on 
chromosome 4q23 (ADH1B, ADH1C, ADH5, ADH6, ADH7)6.  
Here, we report a GWAS meta-analysis of alcohol intake (log transformed g/day) 
among people of European ancestry drawn from UK Biobank (UKB)10, the Alcohol 
Genome-Wide Consortium (AlcGen) and the Cohorts for Heart and Aging Research in 
Genomic Epidemiology Plus (CHARGE+) consortia. Briefly, UKB is a prospective 
cohort study of ~500,000 individuals recruited between the ages of 40 and 69 years. 
Participants were asked to report their average weekly and monthly alcohol 
consumption through a self-completed touchscreen questionnaire10. Based on these 
reports, we calculated the g/d alcohol intake (Methods). Participants were 
genotyped using a customized array with imputation from the Haplotype Reference 
Consortium (HRC) panel11, yielding ~7 million common single nucleotide 
polymorphisms (SNPs) with minor allele frequency (MAF)  1% and imputation 
quality score [INFO]  0.1. After quality control (QC) and exclusions (Methods) we 
performed GWAS of alcohol consumption using data from 404,731 UKB participants 
of European descent under an additive genetic model (Methods and Supplementary 
Table 1). We found that genomic inflation in the UKB analysis was λGC=1.45, but did 
not adjust for inflation as the LD score regression intercept was 1.05, indicating that 
this was due to polygenicity rather than to population stratification12. The estimated 
SNP-wide heritability of alcohol consumption in the UKB data was 0.09. 
We also carried out GWAS in 25 independent studies from the AlcGen and CHARGE+ 
consortia including 76,111 participants of European descent for which alcohol g/d 
could be calculated (Supplementary Table 2). Various arrays were used for 
genotyping, with imputations performed using either the 1,000 Genomes Reference 
Panel or the HRC platforms (Supplementary Table 3). After QC, we applied genomic 
control at the individual study level and obtained summary results for ~7 million 
SNPs with imputation quality score  0.3 (Methods).  
We combined the UKB, AlcGen and CHARGE+ results using a fixed effects inverse 
variance weighted approach for a total of 480,842 individuals13. To maximize power, 
we performed a single-stage analysis to test common SNPs with MAF  1%. We set a 
stringent P-value threshold of P < 5 x 10-9 to denote significance in the combined 
meta-analysis14, and required signals to be at P < 5 x 10-7 in UKB, with same direction 
of effect in UKB and AlcGen plus CHARGE+, to minimize false positive findings. We 
excluded SNPs within 500kb of variants reported as genome-wide significant in 
previous GWAS of alcohol consumption5,6, identified novel loci by requiring SNPs to 
be independent of each other (LD r2 < 0.1), and selected the sentinel SNP within each 
locus according to lowest P-value (Methods).  
We then tested for correlations of alcohol-associated SNPs with Magnetic Resonance 
Imaging (MRI) phenotypes of brain, heart and liver, and gene expression.  We tested 
the sentinel SNPs for association with other traits/diseases and Drosophila mutant 
models were used to investigate functional effects on ethanol-induced behavior.  
RESULTS 
Our meta-analysis identified 46 novel loci associated with alcohol consumption (log 
transformed g/day) (Fig. 1 and Table 1). All inferential statistics for the novel loci are 
reported in Table 1 whereas heterogeneity metrics are presented in Supplementary 
Table 4. In addition, we discovered a further eight variants in the combined analysis 
at nominal genome-wide significance (P < 1 x 10-8) that may also be associated with 
alcohol intake (Supplementary Table 5). The most significantly associated variant, 
rs1991556 (P = 4.5 x 10-23), is an intronic variant in MAPT gene that encodes the 
microtubule-associated protein tau, and was found through Phenoscanner not only 
to be associated with dementia15 and Parkinson’s disease16,17, but also with 
neuroticism, schizophrenia18and other traits19-21 (Methods, Fig. 2 and 
Supplementary Table 6). The second most significantly associated variant is 
rs1004787 (P = 6.7 x 10-17), near SIX3 gene, which encodes a member of the sine 
oculis homeobox transcription factor family involved in eye development22. The third 
SNP is rs13107325 (P = 1.3 x 10-15), a missense SNP in SLC39A8 
(https://www.ncbi.nlm.nih.gov/gene/64116), a gene that encodes a member of the 
SLC39 family of metal ion transporters, which has been associated with 
schizophrenia23 as well as inflammatory bowel disease, cardiovascular and metabolic 
phenotypes 24 25-27 in previous GWAS (Fig. 2 and Supplementary Table 6).  
Another of our most significant variants, an intronic SNP rs7121986 (P = 6.2 x 10-14) 
in DRD2 (https://www.ncbi.nlm.nih.gov/gene/1813), encodes the dopamine 
receptor D2 that has been associated with cocaine addiction, neuroticism and 
schizophrenia18. We also found significant associations with SNP rs988748 (P = 4.4 x 
10-9) in the BDNF gene (https://www.ncbi.nlm.nih.gov/gene/627, that encodes  a
member of the nerve growth factor family of proteins and rs7517344, which is near
ELAVL4 (https://www.ncbi.nlm.nih.gov/gene/1996) (P = 2.0 x 10-10), the gene
product of which is involved in BDNF regulation28. Previous studies have suggested
that a variant in BDNF is associated with alcohol consumption and that alcohol
consumption modulates BDNF expression29.
Additionally, we found association of alcohol consumption with SNP rs838145 (P = 
3.2 x 10-15), which has been associated with macronutrient intake in a previous 
GWAS30. This variant is nearest IZUMO (https://www.ncbi.nlm.nih.gov/gene/284359) 
in a locus of around 50kb that spans a number of genes including FGF21 
(https://www.ncbi.nlm.nih.gov/gene/26291), whose gene product FGF21 is a liver 
hormone involved in the regulation of alcohol preference, glucose and lipid 
metabolism31. We previously reported significant association of alcohol intake with 
SNP rs11940694 in KLB (https://www.ncbi.nlm.nih.gov/gene/152831), an obligate 
receptor of FGF21 in the brain5, and we strongly replicated that finding here (P = 3.3 
x 10-68). 
As well as variants in KLB and in the alcohol dehydrogenase locus (smallest P = 1.2 x 
10-125), we found support (P = 1 x 10-5) for association of common variants in the
three other alcohol intake-related loci previously reported in GWAS (Supplementary
Table 7), including SNP rs6943555 in AUTS2
(https://www.ncbi.nlm.nih.gov/gene/26053) (P = 2.9 x 10-6). In addition, we found a
novel alcohol intake-related SNP rs1421085 in FTO
(https://www.ncbi.nlm.nih.gov/gene/79068) in high LD (r2 = 0.92) with a variant
reported previously as genome-wide significant for association with alcohol
dependence32.
Conditional analysis using Genome-wide Complex Trait Analysis (GCTA) did not 
reveal any independent secondary signals related to alcohol consumption. Among 
~14,000 individuals in the independent Airwave cohort33 (Methods), 7% of the 
variance in alcohol consumption was explained by the novel and known common 
variants. Using weights from our analysis, we constructed an unbiased weighted 
genetic risk score (GRS) in Airwave (Methods) and found a strong association of the 
novel and known variants on alcohol consumption levels (P = 2.75 x 10-14), with mean 
difference in sex-adjusted alcohol intake of 2.6 g/d comparing the top vs the bottom 
quintile of the GRS (Supplementary Table 8).  
 
Associations with MRI imaging phenotypes 
We functionally characterized novel variants by carrying out single-SNP analyses of 
the imaging phenotypes in UKB (Methods), focusing on brain (N=9,702), heart 
(N=10,706) and liver (N=8,479). 
With Bonferroni correction (corrected P-value 6.6 x 10-6, corresponding to 0.05/46 
SNPs*164 imaging phenotypes), we found significant positive associations between 
SNP rs13107325 in SLC39A8 and the volumes of multiple brain regions; All inferential 
statistics for these associations are reported in Supplementary Table 9.  The 
strongest associations were with putamen (left: P = 2.5 x 10-45, right: P = 2.8 x 10-47), 
ventral striatum (left: P = 9.5 x 10-53, right: P = 9.6 x 10-51) and cerebellum (strongest 
association for left I-IV volume; P = 1.2 x 10-9) (Supplementary Table 9); similar 
findings were recently reported in a GWAS on brain imaging in UKB34. The other 
significant association was for rs1991556 with the parahippocampal gyrus (P = 1.2 x 
10-6). 
We then tested these brain regions for association with alcohol consumption and 
found a significant effect for the left (t8601 = -3.7; beta  SE = -0.0019  0.0005; P = 
2.0 x 10-4) and right (t8601 = -3.65; beta  SE = -0.0070  0.0005; P = 2.6 x 10-4) 
putamen. Finally, we used data from N= 8,610 individuals and performed a 
mediation analysis using a standard three-variable path model, bootstrapping 10,000 
times to calculate the significance of the mediation effect of putamen volume for 
genetic influences on alcohol consumption (Methods). We found evidence that the 
effect of SNP rs13107325 in SLC39A8 on alcohol intake is partially mediated via its 
association with left (t8601 = -3.03; beta  SE = -0.27  0.09; P = 1.9 x 10-3) and right 
(t8601 = -2.82; beta  SE = -0.27  0.09; P = 1.7 x 10-3) putamen volume (Fig. 3 and 
Supplementary Table 10). To exclude the possibility of an inverse causal pathway we 
performed additional analyses in UKB non-drinkers (N =589). With 10,000 random 
permutations, associations of rs13107325 with both left and right putamen 
remained significant (left putamen: t541=1.06; P = 0.02; right putamen: t541=0.38; P = 
0.04) indicating that the association between rs13107325 and putamen regions is 
not mediated by alcohol intake.   
We did not find any significant associations of novel SNPs with either cardiac (left 
ventricular mass or end diastolic volume or right ventricular end diastolic volume) 
(Supplementary Table 11) or liver fat measures on MRI (Supplementary Table 12), 
after adjustment for multiple testing. 
Effects of SNPs on gene expression  
We carried out expression quantitative trait loci eQTL analyses using the Genotype-
Tissue Expression (GTEx) and the UK Brain Expression Consortium (UKBEC) datasets; 
34 of the 53 novel and known SNPs associated with alcohol consumption have a 
significant effect on gene expression in at least one tissue, including 33 SNPs that 
affect gene expression in the brain (Supplementary Tables 13 and 14, and 
Supplementary Figures 1-3). We found that the most significant eQTLs often do not 
involve the nearest gene and that several of the SNPs affect expression of different 
genes in different tissues. For example, SNP rs1991556 in the MAPT gene 
(https://www.ncbi.nlm.nih.gov/gene/4137) affects expression of 33 genes overall, 
with most significant effects on the expression of the non-protein coding genes 
CRHR1-IT1 (also known as C17orf69 or LINC02210) 
(https://www.ncbi.nlm.nih.gov/gene/147081) and LRRC37A4P 
(https://www.ncbi.nlm.nih.gov/gene/?term=LRRC37A4P), near MAPT, across a wide 
range of tissues including brain, adipose tissue and skin (P = 7.2 x 10-126 to P = 2.5 x 
10-6) (Supplementary Figure 2). Similarly, the A-allele at SNP rs2071305 within 
MYBPC3 (https://www.ncbi.nlm.nih.gov/gene/4607) affects the expression of 
several genes and is most significantly associated with increased expression of 
C1QTNF4 (https://www.ncbi.nlm.nih.gov/gene/114900) across several tissues (P = 
1.9 x 10-25 to P = 8.4 x 10-5). 
Several of these eQTLs were found to affect expression of genes known to be 
involved in reward and addiction. SNP rs1053651 in the TCAP-PNMT-STARD3 gene 
cluster affects expression of the PPP1R1B gene (also known as DARPP-32) 
(https://www.ncbi.nlm.nih.gov/gene/84152) which encodes a protein that mediates 
the effects of dopamine in the mesolimbic reward pathway35. Other known 
addiction-related genes include 
ANKK1 (https://www.ncbi.nlm.nih.gov/gene/255239) and DRD2 (expression affected 
by SNP rs7121986) implicated in alcohol and nicotine dependence36,37, CRHR1 
(https://www.ncbi.nlm.nih.gov/gene/1394) (affected by SNP rs1991556) involved in 
stress-mediated alcohol dependence38,39 and PPM1G (SNP rs1260326) 
(https://www.ncbi.nlm.nih.gov/gene/5496) whose epigenetic modification was 
reported to be associated with alcohol abuse40. 
Over-representation enrichment analyses based on functional annotations and 
disease-related terms indicated that genes whose expressions are affected by the 
identified eQTLs are most significantly enriched for terms related to abdominal 
(n=91) and other malignant cancers, motor function (n= 5) and cellular homeostasis 
(n= 22) (Supplementary Figure 4). We performed a gene-based analysis and 
repeated the over-representation enrichment analysis adding the new set of 
identified genes (Supplementary Table 15). The results were similar supporting an 
enrichment for abdominal (n=100) and other cancers, as well as motor function 
(n=5) and cellular homeostasis (n=24) (Supplementary Figure 5).   
Other traits and diseases 
 
Using LD score regression12, we assessed genetic correlations between alcohol 
consumption and 235 complex traits and diseases from publicly available summary 
GWAS statistics (Methods).  All results including their statistics (i.e. rg, standard 
errors, z value and P value) are included in Supplementary Table 16. The strongest 
positive genetic correlations based on false discovery rate P < 0.02 were found for 
smoking (rg= 0.42, P = 1.0 x 10-23) and HDL cholesterol levels (rg= 0.26, P = 5.1 x 10-13). 
We also found negative correlations for sleep duration (rg= -0.14, P = 3.8 x 10-7) and 
fasting insulin levels (rg= -0.25, P = 4.5 x 10-6). A significant genetic correlation was 
also found with schizophrenia (rg= 0.07, P = 3.9 x 10-3) and bipolar disorder (rg= 0.15, 
P = 5.0 x 10-4) (Supplementary Table 16). Over-representation enrichment analysis 
using WebGestalt41 (http://www.webgestalt.org) showed that our list of novel and 
known variants is significantly enriched for several diseases and traits including 
developmental disorder in children (P = 7.3 x 10-5), epilepsy (P = 1.4 x 10-4), heroin 
dependence (P = 5.7 x10-4) and schizophrenia (P = 8.4 x 10-4) (Supplementary Figure 
6). The result of the Mendelian randomization analysis (Methods) to assess a 
potential causal effect of alcohol on schizophrenia risk, using the inverse variance 
weighted approach, was not significant (P = 0.089), with large heterogeneity of the 
estimates of the tested variants. 
Functional studies in Drosophila 
Based on our GWAS and brain imaging findings we took forward SNP rs13107325 in 
SLC39A8 (alias Zip8 gene) for additional testing in Drosophila, which employ 
conserved mechanisms to modulate ethanol-induced behaviors42,43. First, we 
overexpressed human Zip8 using a Gal4-driver that included expression in neurons 
involved in multiple ethanol-induced behaviors43. Flies carrying icsGal4/+ UAS-
hZip8/+ showed a slight, but significant, resistance to ethanol-induced sedation 
compared to control flies (t30 = 2.3; Hedge’s g = 0.80; 95% CI: 0.08 – 1.53; P = 0.026; 
N = 16 per genotype). Ethanol tolerance, induced with repeat exposures spaced by a 
4-hour recovery, was unchanged in these flies (t = 1.0; P = 0.33; Fig. 4a). We next 
used the same Gal4-driver to knock down the endogenous Drosophila ortholog 
of hZip8, namely dZip71B. This caused the flies to display naïve sensitivity to ethanol-
induced sedation (t14 = 3.98; Hedge’s g = -1.84; 95% CI: -0.67 – -3.01; P = 0.0014; N = 
8 per genotype), and in addition, these flies developed greater tolerance to ethanol 
upon repeat exposure (t14 = 4.80; Hedge’s g = 2.29; 95% CI: 1.03 – 3.55; P = 0.0003; 
Fig. 4b). To corroborate this phenotype, we then tested flies transheterozygous for 
two independent transposon-insertions in the middle of the dZip71B gene 
(Supplementary Figure 7) and found that these dZip71BMi / MB flies also displayed 
naïve sensitivity (t14 = 3.23; Hedge’s g = -1.54; 95% CI: -0.42 – -2.65; P = 0.006) and 
increased ethanol-induced tolerance (t14 = 2.39; Hedge’s g = 1.13; 95% CI: 0.07 - 
2.18; P = 0.032) compared to controls (N = 8 each) (Fig. 4c). 
 
DISCUSSION 
Our discovery utilizing data on common variants from over 480,000 people of 
European descent extends our knowledge of the genetic architecture of alcohol 
intake, increasing the number of identified loci to 46.  We found loci involved in 
neuropsychiatric conditions such as schizophrenia, Parkinson’s disease and 
dementia, as well as BDNF where gene expression is affected by alcohol abuse. Our 
findings illustrate that large-scale studies of genetic associations with alcohol intake 
in the general population, rather than on alcohol dependency alone, can provide 
additional insights into genetic mechanisms regulating alcohol consumption. 
We highlight the role of the highly pleiotropic MAPT and SLC39A8 genes in the 
genetics of alcohol consumption. MAPT plays a key role in tau-associated dementia44 
and both genes are also implicated in other neuropsychiatric conditions including 
neuroticism, schizophrenia and Parkinson’s disease16-18. The SLC39A8 gene encodes a 
member of the SLC39 family of metal ion transporters. The encoded protein is 
glycosylated and found in plasma membrane and mitochondria, and is involved in 
the cellular transport of zinc, modulation of which could affect microglial 
inflammatory responses45. Our gain- and loss-of-function studies in Drosophila 
indicate a potential causal role of SLC39A8 in alcohol drinking behavior, even though 
results should be interpreted with caution due to small sample size in our 
experiment. The MRI brain imaging demonstrates a significant association of SNP 
rs13107325 in the SLC39A8 gene and putamen volume differences, and these 
structural differences appear to partially mediate associations of rs13107325 with 
alcohol consumption.  The putamen has been associated with alcohol consumption 
and the withdrawal syndrome after chronic administration to rodents and non-
human primates46. Our mediation analysis is suggestive of a plausible causal pathway 
linking rs13107325 in SLC39A8 with alcohol intake via an effect on putamen volume, 
but follow-up work is needed to conclusively demonstrate causal links. Putamen 
volume differences have also been associated with both schizophrenia and 
psychosis47,48 and robust association between SNP rs13107325 in SLC39A8 and 
schizophrenia was reported in a previous GWAS23.  
We also report SNP rs7121986 near DRD2 as a novel alcohol intake variant in GWAS. 
The gene product of DRD2, D2 dopamine receptor, is a G protein-coupled receptor 
on post-synaptic dopaminergic neurons that has long been implicated in 
alcoholism49. In addition, we identify SNP rs988748 in BDNF as a novel alcohol intake 
variant; BDNF expression is differentially affected by alcohol exposure in animal 
models50,51. Both genes (along with PPP1R1P) are centrally involved in reward-
mediating mesocortico-limbic pathways and both are implicated in the development 
of schizophrenia. For example, there is a robust GWAS association between 
schizophrenia and SNP rs4938021 in DRD2 (in perfect LD with our novel alcohol 
intake-related variant rs7121986) and DRD2 appears to be pivotal in network 
analyses of genes involved in schizophrenia52.  Taken together, our results suggest 
that there are shared genetic mechanisms between the regulation of alcohol intake 
and susceptibility to schizophrenia, as well as other neuropsychiatric disorders. In 
this regard, large prospective epidemiological studies report a three-fold risk of 
schizophrenia in relation to alcohol abuse53.  
We previously reported genome-wide significant associations of alcohol intake with 
KLB, and identified a liver-brain axis linking the liver hormone FGF21 with central 
regulation of alcohol intake involving β-Klotho receptor (the gene product of KLB) in 
the brain5. Here, we identify a significant variant near FGF21 gene and strongly 
replicate the previously reported KLB gene variant, strengthening the genetic 
evidence for the importance of this pathway in regulating alcohol consumption.  
The LD score regression analysis showed a positive genetic correlation between 
alcohol consumption, smoking and HDL cholesterol levels. This confirms previous 
findings that reported an almost identical genetic correlation of alcohol consumption 
with number of cigarettes per day54. Furthermore, the observed genetic correlation 
with HDL levels is consistent with previous observations of an association between 
alcohol consumption and HDL55,56, including results of a Mendelian randomization 
study that suggested a possible causal role linking alcohol intake with increased HDL 
levels57.  Furthermore, we found a genetic correlation (inverse) between sleep 
duration and alcohol consumption, an association previously reported only in a few 
small epidemiological studies58. We also found a significant genetic correlation with 
schizophrenia and bipolar disorder, a result that is supported by a recently published 
trans-ethnic meta-analysis of case-control studies on alcohol dependence59. We 
could not test for a genetic association between alcohol and risk of alcohol-related 
cancers60 because of limited availability of summary data. However, our gene-set 
enrichment analysis showed a significant enrichment for genes related to abdominal 
as well as other cancers.   
Strengths of our study include its size, detailed attention to the alcohol phenotype, 
dense coverage of the genome through imputation, and incorporation of brain and 
other imaging data to explore potential mechanisms. Over 80% of the data came 
from UKB, which combines high-quality phenotypic data and imputed genome-wide 
genetic data with strict attention to quality control61. We adopted a stringent 
approach to claim novel variants involving a conservative P-value threshold, internal 
replication in UKB and consistent direction of effect with the other studies, to 
minimize the reporting of false positive signals. 
However, since alcohol intake is socio-culturally as well as genetically determined, it 
is influenced by other lifestyle and environmental factors which may modify or dilute 
the genetic signal. A key limitation is that assessment of alcohol intake relies on self-
report, which is prone to errors and biases including recall bias and systematic 
under-reporting by heavy drinkers62,63. Furthermore, questionnaires on alcohol 
intake covered a short duration (e.g. day or week) at a single period, which may not 
be representative of broader drinking patterns of cohort participants. We 
harmonized data across cohorts by converting alcohol intake into a common metric 
of g/d, with imputation as necessary in UKB for participants reporting consumption 
of small amounts of alcohol. Taking this approach, we were able to detect strong 
genetic associations with alcohol intake that explained 7% of the variance in alcohol 
in an independent cohort, while our GRS analysis indicates that individuals in the 
lower fifth of the GRS distribution were consuming daily approximately one third of a 
standard drink (2.6 g/d alcohol) less compared with those in the upper fifth.   
We should also point out that our eQTL analyses are a first step in the identification 
of causal genes. Yet, as the most significant eQTLs affected expression of many 
genes, not necessarily the nearest, there is a need to further prioritize potential 
causal genes. Unbiased strategies that leverage information from multiple data sets 
including extensive genomic annotations and high-throughput functional screening 
in a broad range of tissues will be essential for effective prioritization of genes and 
uncovering of underlying causal mechanisms64. Establishing confidence in the 
prioritized genes in such a way is a prerequisite for performing functional follow-up 
studies in appropriate model systems, as demonstrated by the identification of the 
causal genes and potential disease mechanisms at the obesity- associated FTO 
locus65. 
 
In summary, in this large study of genetic associations with alcohol consumption, we 
identified common variants in 46 novel loci, with several of the genes expressed in 
the brain as well as other tissues. Our findings suggest that there may be shared 
genetic mechanisms underpinning regulation of alcohol intake and development of a 
neuropsychiatric disorders including schizophrenia. This may form the basis for 
greater understanding of observed associations between alcohol consumption, 
schizophrenia66 and other disorders. 
METHODS 
 
UK Biobank data 
We conducted a Genome Wide Association Study (GWAS) analysis among 458,577 
UKB participants of European descent, identified from a combination of self-reported 
and genetic data. The details of the selection of the participants has been described 
elsewhere14. These comprise 408,951 individuals from UKB genotyped at 825,927 
variants with a custom Affymetrix UK Biobank Axiom Array chip and 49,626 individuals 
genotyped at 807,411 variants with a custom Affymetrix UK BiLEVE Axiom Array chip 
from the UK BiLEVE study, which is a subset of UKB. For our analyses, we used SNPs 
imputed centrally by UKB using the Haplotype Reference Consortium (HRC) panel.  
 
Alcohol intake  
We calculated the alcohol intake as grams of alcohol per day (g/d) based on self-
reported alcohol drinking from the touch-screen questionnaire. The quantity of each 
type of drink (red wine, white wine, beer/cider, fortified wine, spirits) was multiplied 
by its standard drink size and reference alcohol content. Drink-specific intake during 
the reported drinking period (a week for frequent drinkers defined as: daily or almost 
daily/once or twice a week/three or four times a week; or a month for occasional 
drinkers defined as: one to three times a month/special occasions only) was summed 
up and converted to g/d alcohol intake for all participants with complete response to 
the quantitative drinking questions. The alcohol intake for participants with 
incomplete response was imputed by bootstrap resampling from the complete 
responses, stratified by drinking frequency (occasional or frequent) and sex.   
 
Participants were defined as life-time non-drinkers if they reported ‘never’ on the 
question on alcohol drinking frequency (UKB field 1558) and ‘no’ for the question on 
former drinker (UKB field 3731); they were excluded from further analysis. We 
considered participants with alcohol consumption > 500 g/d as outliers and they were 
dropped from the analyses. We also excluded participants with missing covariates, 
leaving data on 404,732 individuals.  We log10 transformed g/d alcohol and sex-specific 
residuals were derived from the regression of log10 transformed g/d alcohol on age, 
age2, genotyping chip and weight.  
 
UKB genetic analysis  
We performed linear mixed modeling using BOLT-LMM software67, under an additive 
genetic model, for associations of measured and imputed SNPs with alcohol 
consumption (sex-specific residuals of the log10 transformed g/d variable). Model 
building was based on SNPs with MAF > 5%, call rate > 98.5% and HWE P > 1 x 10-6. 
SNPs were imputed using the HRC panel with imputation quality INFO score > 0.1. We 
estimated the LD score regression (LDSR) intercept to assess the degree of genomic 
inflation beyond polygenicity as well as the lambda inflation factor λGC68.  
The Alcohol Genome-Wide Consortium (AlcGen) and the Cohorts for Heart and Aging 
Research in Genomic Epidemiology Plus (CHARGE+) consortia  
We analyzed available GWAS data from 25 independent studies (N=76,111) from the 
AlcGen and the CHARGE+ consortia. All study participants were of reported European 
ancestry and data were imputed to either the 1000 Genome Project or the HRC panel. 
Alcohol intake in g/d was computed and the log10 transformed residuals were analyzed 
as described above. Study names, cohort information and general study methods are 
included in Supplementary Table 2 and 3. 
All studies were centrally quality-controlled using easyQC69 including filtering for MAF. 
Finally, we analyzed data on ~7.1 M SNPs at MAF >1% and imputation quality score 
(Impute [Info score] or Mach [r2]) > 0.3. Genomic control (GC) was applied at study 
level. We synthesized the available GWAS using a fixed effects inverse variance 
weighted meta-analysis and summary estimates were derived for AlcGen and 
CHARGE+.  
One-stage meta-analysis 
We performed a one-stage meta-analysis applying a fixed-effects inverse variance 
weighted meta-analysis using METAL70 to obtain summary results from the UKB and 
and the AlcGen plus CHARGE+ GWAS, for up to N=480,842 participants and ~7.1 M 
SNPs with MAF ≥ 1% for variants present in both the UKB data and AlcGen and 
CHARGE+ meta-analysis. We assessed the observed heterogeneity using Cochran’s Q 
and we quantified this using the I2 metric. We considered a Cochran’s Q  P < 1 × 10-4 
as significant. The LDSR intercept (standard error), in the discovery meta-analysis was 
1.05 and no further correction was applied. QQ plots of the combined meta-analysis 
summary results , UK Biobank only as well as AlcGen and CHARGE+ only, are presented 
in Supplementary Figure 8.  
 
Previously reported (known) SNPs 
We looked up in the GWAS catalog (http://www.ebi.ac.uk/gwas/) and identified 17 
SNPs associated with alcohol consumption at genome-wide significance level (P < 5 × 
10-8). We enhanced the list by reference to a recent GWAS by Clarke et al6 that was 
not covered by the GWAS catalog at the time of the analysis, reporting 14 additional 
rare and common SNPs. Together with a SNP in RASGRF2 shown to be associated with 
alcohol-induced reinforcement71, we found 31 previously reported alcohol 
consumption related SNPs.  
 
Novel loci 
According to locus definition of i) SNPs within 500kb distance of each other; ii) SNPs 
in linkage disequilibrium LD (r2 > 0.1) calculated with PLINK, we augmented the list of 
known SNPs with all SNPs present within our data, not contained within the previously 
published loci. We further excluded SNPs in the HLA region (chromosome 6, 25-34Mb) 
due to its complex LD structure. We performed LD clumping in PLINK on 4,515 
unknown SNPs with P < 1 10-8 using an r2 > 0.1 and distance threshold of 500kb. We 
further grouped the lead SNPs within 500kb from each other into the same loci and 
selected the SNP with smallest P-value from the locus as sentinel SNP.  
To report a SNP as novel signal of association with alcohol consumption: 
´
i) the sentinel SNP has P < 5 × 10-9 in the one-stage meta-analysis;  
ii) the sentinel SNP is strongly associated (P < 5 × 10-7) in the UKB GWAS alone; 
iii) the sentinel SNP has concordant direction of effect between UKB and 
AlcGen and CHARGE+ datasets; 
iv) The sentinel SNP is not located within any of the previously reported loci 
We selected the above criteria i) to iii) to minimize false positive findings including use 
of a conservative one-stage P-value threshold that is an order of magnitude more 
stringent than a genome-wide significance P-value. (The threshold of P < 5 × 10-9 has 
been proposed e.g. for whole-genome sequencing-based studies.) This approach led 
us to the identification of 46 sentinel SNPs in total. Regional plots for all 46 sentinel 
SNPs are presented in Supplementary Figure 9. 
 
Conditional analysis 
We conducted locus-specific conditional analysis using the GCTA (Genome-wide 
Complex Trait Analysis) software (http://cnsgenomics.com/software/gcta). For each 
of the 46 novel sentinel SNPs, we obtained conditional analysis results for the SNPs 
with MAF>1% and within 500kb from the sentinel SNP after conditioning on the 
sentinel SNP. The meta-analysis results of the GWAS in UKB, AlcGen and CHARGE+ 
were used as input summary statistics and the individual-level genetic data from UKB 
were used as the reference sample. Results for a SNP were considered conditionally 
significant if the difference between the conditional P-value and the original P-value 
is greater than 1.5-fold (-log10P/-log10(P_conditional) >1.5) and the conditional P-
value is smaller than 5 × 10-8.  
 
Gene-based analysis  
We performed a gene-based analysis using fastBAT, a method that performs a set-
based association analysis using summary-level data from GWAS. We used the UKB 
dataset as a reference set for the LD calculation72. Gene-based associations with P < 
5 × 10-9 were considered significant.   
 
Gene expression analyses 
To analyze the impact of genetic variants on expression of neighboring genes and 
identify expression quantitative trait loci (cis-eQTLs; i.e., SNPs associated with 
differences in local gene expression), we used two publicly available databases, the 
Genotype-Tissue Expression (GTEx) database73 (www.gtexportal.org) and the UK Brain 
Expression Consortium (UKBEC) dataset74 (http://www.braineac.org). We searched 
these databases for significant variant-transcripts pairs for genes within 1Mb of each 
input SNP. 
With the GTEx database, we tested for cis-eQTL effects in 48 tissues from 620 donors. 
The data described herein were obtained from the GTEx Portal, Release: V7 and used 
FastQTL75, to map SNPs to gene-level expression data and calculate q-values based on 
beta distribution-adjusted empirical P-values76. A false discovery rate (FDR) threshold 
of ≤0.05 was applied to identify genes with a significant eQTL. The effect size, defined 
as the slope of the linear regression, was computed in a normalized space (normalized 
effect size (NES)), where magnitude has no direct biological interpretation. Here, NES 
reflects the effects of our GWAS A1 alleles (that are not necessarily the alternative 
alleles relative to the reference alleles, as reported in the GTEx database). 
Supplementary Table 13 lists transcripts-SNPs associations with significant eQTL 
effects. 
With the UKBEC dataset that comprises 134 brains (http://www.braineac.org/), we 
searched for cis-eQTLs in 10 brain regions, including the cerebellar cortex (CRBL), 
frontal cortex (FCTX), hippocampus (HIPP), medulla (specifically inferior olivary 
nucleus, MEDU), occipital cortex (specifically primary visual cortex, OCTX), putamen 
(PUTM), substantia nigra (SNIG), thalamus (THAL), temporal cortex (TCTX) and 
intralobular white matter (WHMT), as well as across all brain tissues (aveALL). 
MatrixEQTL77 generated P-values for each expression profile (either exon-level or 
gene-level) against the respective SNP were obtained for the 10 different tissues and 
overall (aveALL). Supplementary Table 14 lists transcripts-SNPs associations with a 
eQTL P-value < 0.0045 in at least one brain tissue. Subsequent data analysis was 
performed in R (http://www.R-project.org/). 
We carried out over-representation enrichment analysis using a list of 146 GTEx eQTL 
genes that were derived from the single-variant analysis and a list of 160 eQTL genes 
that were derived from both single-variant and gene-based analysis. Ingenuity 
pathway analysis (IPA®, QIAGEN Inc.) was performed on these lists using ontology 
annotations from all available databases except those derived from low-confidence 
computational predictions.  
Magnetic Resonance Imaging Data 
We used the most recent release of magnetic resonance imaging (MRI) data on brain, 
heart and liver for UKB participants to investigate genetic associations with the 46 
novel SNPs for alcohol consumption.   
 
Brain imaging  
 
Brain MRI acquisition and pre-processing 
We used the T1 data from UKB to elucidate volumetric brain structures, including the 
cortical and the sub-cortical areas. The T1 data were acquired and pre-processed 
centrally by UKB. The brain regions were defined by combining the Harvard-Oxford 
cortical and subcortical atlases78 (https://fsl.fmrib.ox.ac.uk/fsl/fslwiki/Atlases) and 
the Diedrichsen cerebellar atlas79 
(http://www.diedrichsenlab.org/imaging/propatlas.htm). FAST (FMRIB’s Automated 
Segmentation Tool)80 was then used to estimate the grey matter partial volume 
within each brain region. Subcortical region volumes were also modelled by using 
FIRST (FMRIB’s Integrated Registration and Segmentation Tool). More details about 
the MRI scanning protocol and pre-processing has been provided in UKB 
documentation (https://biobank.ctsu.ox.ac.uk/crystal/docs/brain_mri.pdf). 
Association Analyses 
We performed association analyses on N = 9,702 individuals between all novel SNPs 
and the grey matter volume of brain regions using Pearson correlation, adjusting for 
age, age2, sex, age × sex, age2 × sex, and head size. All, brain volume features, log 
transformed alcohol intake data (g/d), and the confounders were firstly transformed 
by using a rank-based inverse Gaussian transformation. Significance levels were set at 
P < 0.05 adjusted using the false-discovery rate method for multiple comparisons.  
 
Mediation analysis 
To assess if the effect of a SNP on alcohol consumption is mediated through a brain 
region, we performed a single-level mediation analysis based on a standard three-
variable path model (SNP-brain region-alcohol consumption) with corrected and 
accelerated percentile bootstrapping 10,000 times to calculate the significance of the 
mediation effect. We considered as mediator variable the grey matter volume of brain 
regions that had a significant association on alcohol consumption. We calculated the 
significance of path a, path b and a*b mediation (SNP-brain region-alcohol 
consumption) using a multilevel mediation and moderation (M3) toolbox81,82. To 
exclude the possibility of an inverse causal pathway we performed additional analyses 
in UKB non-drinkers (N =589). performing 10,000 random permutations, associations 
of rs13107325 with both left and right putamen. 
 
Cardiac Imaging  
 
Cardiac MRI acquisition and pre-processing 
Details of the cardiac image acquisition in UKB are reported previously83. Cardiac MRI 
was acquired using a clinical wide bore 1.5T scanner (MAGNETOM Aera, Syngo 
Platform VD13A, Siemens Healthcare, Erlangen, Germany) with 48 receiver channels, 
a 45 mT/m and 200 T/m/s gradient system, an 18-channel anterior body surface coil 
used in combination with 12 elements of an integrated 32 element spine coil and 
electrocardiogram gating for cardiac synchronization. A two-dimensional short-axis 
cardiac MRI was obtained using a balanced steady state free precession to cover the 
entire left and right ventricle (echo time, 1.10msec; repetition time, 2.6msec; flip 
angle, 80°; slice thickness, 8mm with 2mm gap; typical field of view, 380×252mm; 
matrix size, 208×187, acquisition of 1 slice per breath-hold). 
The cardiac images were segmented to provide left ventricular mass (LVM), left end-
diastolic (LVEDV), left end-systolic volume (LVESV), and right end-diastolic (RVEDV) 
and right end-systolic volume (RVESV) using a fully convolutional network as described 
previously84. Left (LVEF) and right ventricular ejection fraction (RVEF) were derived 
from (LVEDV–LVESV)/LVEDV×100 and (RVEDV–RVESV)/RVEDV×100, respectively. 
Association Analyses 
To test associations between cardiac MRI measures and alcohol consumption-related 
SNPs, we carried out a regression of LVM, LVEDV, LVEF, RVEDV, and RVEF onto each 
of the 46 SNPs adjusting for age, sex, height, weight, hypertension (defined as systolic 
blood pressure >140mmHg and or diastolic blood pressure >90mmHg or under 
antihypertensive treatment), diabetes, and smoking history on N=10,706 participants.  
Significance levels were set at P < 0.05 adjusted using the false-discovery rate method 
for multiple comparisons.  
 
Liver Imaging  
Liver MRI acquisition and pre-processing 
Details of the liver image acquisition protocol have been reported previously85. Briefly, 
all participants were scanned in a Siemens MAGNETOM Aera 1.5-T MRI scanner 
(Siemens Healthineers, Erlangen, Germany) using a 6-minute dual-echo Dixon Vibe 
protocol, providing a water and fat separated volumetric data set for fat and muscle 
covering neck to knees. For liver proton density fat fraction (PDFF) quantification, an 
additional single multi-echo gradient slice was acquired over the liver. Liver images 
were analysed by computing specific ROI for water, fat and T2* by magnitude-based 
chemical shift technique with a 6-peak lipid model, correcting for T1 and T2*. 
 
Association Analyses 
 
We performed association analyses between 46 alcohol consumption-related SNPs 
and liver PDFF (%), from 8,479 samples, using a linear regression model adjusting for 
age, age2, sex, T2D, BMI, genotyping chip and first three PCs. Liver PDDF was firstly 
transformed by using a rank-based inverse transformation. Significance levels were 
set at P < 0.05 adjusted using the false-discovery rate method for multiple 
comparisons.  
 
Drosophila experiments 
Flies were kept on standard cornmeal/molasses fly food in a 12:12hr light:dark cycle 
at 25°C.  Transgenc flies were obtained from the Bloomington Drosophila Stock 
Center: UAS-hZip8 BL#66125, UAS-dZIP71B-TRiP-RNAiHMC04064 BL#55376, 
dZip71BMI13940 BL#59234, and dZip71BMB11703 BL#29928.  For behavioral experiments, 
crosses were set up such that experimental and control flies were sibling progeny 
from a cross, and both were therefore in the same hybrid genetic background (w 
Berlin / unknown).  Flies aged 1-5 days of adult age were collected, exposed to 
100/50 (flowrates) ethanol/air vapor in the Booze-o-Mat 2 days later, and their loss 
of righting determined by slight tapping, as described86.  For tolerance, flies were put 
back onto regular food after a 30-min initial exposure and were then re-exposed to 
the same vapor 4 hours later.  Note that tolerance is not connected to initial 
sensitivity, and flies naively sensitive to ethanol-induced sedation can have no, or a 
reduced tolerance phenotype. Flies overexpressing hZip8 (and their sibling controls) 
were placed at 28°C for two days to increase the expression levels of the transgene, 
as we did not detect a phenotype when they were kept at 25°C (data not shown).  
Data from experimental and control flies were compared by two-sided Student’s t-
tests. Data were normally distributed according to Shapiro-Wilk testing with 
Bonferroni adjustment for each of the three experiments.  
 
Effects on other traits and diseases 
We queried SNPs against GWAS results included in PhenoScanner 
(http://www.phenoscanner.medschl.cam.ac.uk), to investigate cross-trait effects, 
extracting all association results with genome-wide significance at P < 5 × 10-8 for all 
SNPs in high LD (r2 ≥ 0.8) with the 46 sentinel novel SNPs, to highlight the loci with 
strongest evidence of association with other traits. At the gene level, 
overrepresentation enrichment analysis (ORA) with WebGestalt41 on the nearest 
genes to all alcohol consumption loci was carried out.  
The genetic correlations between alcohol consumption and 235 other traits and 
diseases were obtained in the online software LD Hub. LD hub is a centralized database 
of summary-level GWAS results and a web interface for LD score regression analysis  
To estimate the potential causal effect of alcohol consumption-related variants on 
schizophrenia, we performed a Mendelian randomization analysis utilizing publicly 
available GWAS data on schizophrenia and the Mendelian randomization package in 
R. The effect was estimated using the inverse-variance weighted (IVM) method. 
Pleiotropy was tested by applying the MR-Egger regression method and heterogeneity 
statistics were obtained. In presence of heterogeneity the random effects inverse-
variance method was applied87.  
Genetic risk scores and percentage of variance explained 
We calculated an unbiased weighted GRS in 14,004 unrelated participants in 
Airwave, an independent cohort with high quality HRC imputed genetic data33. All 
previously reported and novel variants were used for the construction of the GRS. 
We weighted the alcohol-increasing alleles by the beta coefficients of the meta-
analysis. We assessed the association of the GRS with alcohol intake and calculated 
the alcohol consumption levels for individuals in the top vs the bottom quintiles of 
the distribution. To calculate the percent of variance of alcohol consumption 
explained by genetic variants, we generated the residuals from a regression of 
alcohol consumption in Airwave. We then fit a second linear model for the trait 
residuals with all novel and known variants plus the top 10 principal components and 
estimated the percentage variance of the dependent variable explained by the 
variants.  
Statistical analysis 
All inferential statistics for the analyses described above are provided in the text or 
in tables and figures. All performed tests were two-sided.  
Data availability statement 
The UKB GWAS data can be assessed from the UK Biobank data repository 
(http://biota.osc.ox.ac.uk/). The genetic and phenotypic UKB data are available upon 
application to the UK Biobank (https://www.ukbiobank.ac.uk). Summary GWAS data 
data can be assessed by request to the corresponding authors and will be available via 
LDHub (http://ldsc.broadinstitute.org/ldhub/). 
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Table 1:  Association results of 46 novel alcohol variants identified through the meta-analysis of UK Biobank and AlcGen and CHARGE+. Results are 
ordered by P-value of combined analysis. 
leadSNP Combined UKB AlcGen and CHARGE+ 
Nearest_Gene 
Annotated 
Gene 
rsID_LEAD_
SNP 
CP EA EAF BETA SE P BETA SE P BETA SE P 
MAPT STH rs1991556 17:44083402 A 0.22 -0.012 0.001 4.5E-23 -0.013 0.001 2.4E-21 -0.011 0.004 4.0E-03 
RP11-89K21.1 SIX3 rs1004787 2:45159091 A 0.54 0.009 0.001 6.7E-17 0.009 0.001 1.1E-15 0.007 0.003 1.4E-02 
SLC39A8 SLC39A8 rs13107325 4:103188709 T 0.07 -0.016 0.002 1.3E-15 -0.017 0.002 4.8E-16 -0.006 0.006 3.6E-01 
IZUMO1, RASIP1, FUT1 IZUMO1 rs838145 19:49248730 A 0.55 -0.008 0.001 3.2E-15 -0.009 0.001 2.4E-15 -0.004 0.003 1.7E-01 
na PSMD7 rs1104608 16:73912588 C 0.43 -0.008 0.001 1.2E-14 -0.009 0.001 4.9E-15 -0.003 0.003 2.5E-01 
MYBPC3 MYBPC3 rs2071305 11:47370957 A 0.69 0.009 0.001 4.5E-14 0.009 0.001 3.9E-13 0.007 0.003 3.1E-02 
na DRD2 rs7121986 11:113355444 T 0.37 -0.008 0.001 6.2E-14 -0.008 0.001 1.3E-13 -0.005 0.003 1.1E-01 
na DPP6 rs6969458 7:153489725 A 0.47 0.008 0.001 6.4E-14 0.008 0.001 1.3E-12 0.007 0.003 1.5E-02 
RP11-308N19.1 ZNF462 rs74424378 9:109331094 T 0.76 0.009 0.001 1.7E-13 0.009 0.001 4.5E-13 0.006 0.003 8.4E-02 
ARHGAP15, AC096558.1, RP11-
570L15.2 
ARHGAP15 rs13024996 2:144225215 A 0.37 -0.008 0.001 4.4E-13 -0.008 0.001 6.6E-13 -0.004 0.003 1.4E-01 
MLXIPL MLXIPL rs34060476 7:73037956 A 0.87 -0.011 0.002 5.0E-13 -0.012 0.002 1.4E-13 -0.004 0.004 4.1E-01 
na FAM178A rs61873510 10:102626510 T 0.33 -0.008 0.001 5.1E-13 -0.008 0.001 9.8E-12 -0.008 0.003 1.7E-02 
FTO FTO rs1421085 16:53800954 T 0.60 0.008 0.001 9.2E-13 0.007 0.001 1.7E-10 0.010 0.003 9.2E-04 
na PMFBP1 rs11648570 16:72356964 T 0.89 -0.012 0.002 2.1E-12 -0.011 0.002 1.5E-10 -0.013 0.005 3.4E-03 
OTX2, RP11-1085N6.6 OTX2 rs2277499 14:57271127 T 0.34 -0.008 0.001 2.2E-12 -0.007 0.001 2.4E-09 -0.012 0.003 9.1E-05 
PDE4B PDE4B rs2310752 1:66392405 A 0.43 -0.007 0.001 2.8E-12 -0.008 0.001 1.8E-11 -0.006 0.003 4.2E-02 
SERPINA1 SERPINA1 rs112635299 14:94838142 T 0.02 -0.025 0.004 3.7E-12 -0.027 0.004 9.8E-12 -0.017 0.010 9.9E-02 
na AJAP1 rs780569 1:4569436 A 0.71 -0.008 0.001 5.2E-12 -0.008 0.001 1.1E-11 -0.005 0.003 1.2E-01 
na VRK2 rs10496076 2:57942987 T 0.37 -0.007 0.001 9.7E-12 -0.007 0.001 1.3E-09 -0.009 0.003 1.6E-03 
ACTR10, C14orf37 ACTR10 rs71414193 14:58685301 A 0.19 -0.009 0.001 1.8E-11 -0.008 0.001 5.8E-09 -0.013 0.004 4.5E-04 
BEND4 BEND4 rs16854020 4:42117559 A 0.13 0.010 0.002 2.9E-11 0.010 0.002 5.8E-09 0.016 0.005 6.4E-04 
na SORL1 rs485425 11:121544984 C 0.45 -0.007 0.001 6.1E-11 -0.007 0.001 7.3E-11 -0.004 0.003 1.9E-01 
SEZ6L2 SEZ6L2 rs113443718 16:29892184 A 0.31 -0.007 0.001 7.4E-11 -0.008 0.001 4.5E-11 -0.003 0.003 2.9E-01 
CBX5, RP11-968A15.2 CBX5 rs57281063 12:54660427 A 0.41 0.007 0.001 7.9E-11 0.007 0.001 1.8E-09 0.007 0.003 1.2E-02 
na TNRC6A rs72768626 16:24693048 A 0.94 0.014 0.002 9.7E-11 0.015 0.002 1.7E-09 0.014 0.006 1.8E-02 
SYT14 SYT14 rs227179 1:210216731 A 0.59 -0.007 0.001 1.1E-10 -0.007 0.001 1.4E-09 -0.006 0.003 2.8E-02 
TCF4 TCF4 rs9320010 18:53053897 A 0.60 0.007 0.001 1.1E-10 0.007 0.001 1.6E-09 0.007 0.003 2.2E-02 
SBK1 NPIPB6 rs2726034 16:28336882 T 0.68 0.007 0.001 1.4E-10 0.007 0.001 1.1E-09 0.006 0.003 4.7E-02 
ANKRD36 ANKRD36 rs13390019 2:97797680 T 0.87 0.010 0.002 1.6E-10 0.011 0.002 7.0E-11 0.004 0.005 4.5E-01 
na ELAVL4 rs7517344 1:50711961 A 0.17 0.009 0.001 1.9E-10 0.008 0.001 2.5E-07 0.016 0.004 2.1E-05 
LINC00461 MEF2C rs4916723 5:87854395 A 0.58 0.007 0.001 2.1E-10 0.007 0.001 5.1E-10 0.005 0.003 1.1E-01 
ARPC1B, ARPC1A ARPC1B rs10249167 7:98980879 A 0.87 0.010 0.002 2.9E-10 0.009 0.002 8.1E-08 0.015 0.004 3.8E-04 
EFNB3, WRAP53 EFNB3 rs7640 17:7606722 C 0.80 0.008 0.001 4.3E-10 0.009 0.001 1.3E-09 0.006 0.004 9.9E-02 
RP11-501C14.5 IGF2BP1 rs4794015 17:47067826 A 0.41 0.007 0.001 4.3E-10 0.006 0.001 5.4E-08 0.009 0.003 1.2E-03 
TCAP, PNMT, STARD3 TCAP rs1053651 17:37822311 A 0.27 -0.007 0.001 1.1E-09 -0.008 0.001 8.4E-10 -0.003 0.003 2.8E-01 
na AADAT rs7698119 4:171070910 A 0.49 -0.006 0.001 1.3E-09 -0.006 0.001 1.6E-07 -0.009 0.003 1.6E-03 
STAT6, AC023237.1 STAT6 rs12312693 12:57511734 T 0.55 -0.006 0.001 1.5E-09 -0.006 0.001 9.5E-09 -0.005 0.003 5.6E-02 
SCN8A SCN8A rs7958704 12:51984349 T 0.41 -0.006 0.001 1.6E-09 -0.006 0.001 1.7E-08 -0.006 0.003 3.5E-02 
ACSS3 ACSS3 rs11114787 12:81595700 T 0.27 0.007 0.001 2.0E-09 0.007 0.001 2.7E-08 0.007 0.003 2.4E-02 
RP11-32K4.1 BHLHE22 rs2356369 8:64956882 T 0.52 -0.006 0.001 2.0E-09 -0.006 0.001 4.1E-08 -0.007 0.003 1.6E-02 
ZRANB2-AS2 ZRANB2 rs12031875 1:71585097 A 0.82 -0.008 0.001 2.2E-09 -0.008 0.001 7.6E-08 -0.010 0.004 8.7E-03 
MSANTD1, HTT MSANTD1 rs12646808 4:3249828 T 0.66 0.007 0.001 2.4E-09 0.007 0.001 1.1E-09 0.002 0.003 4.7E-01 
TENM2 TENM2 rs10078588 5:166816176 A 0.52 0.006 0.001 2.5E-09 0.006 0.001 4.3E-08 0.007 0.003 1.9E-02 
IGSF9B IGSF9B rs748919 11:133783232 T 0.79 0.008 0.001 3.3E-09 0.008 0.001 1.0E-08 0.005 0.003 1.1E-01 
AC010967.2 GPR75-ASB3 rs785293 2:53023304 A 0.57 -0.006 0.001 3.3E-09 -0.006 0.001 3.2E-08 -0.006 0.003 3.8E-02 
BDNF, RP11-587D21.4 BDNF rs988748 11:27724745 C 0.21 -0.008 0.001 4.4E-09 -0.007 0.001 1.2E-07 -0.010 0.004 8.3E-03 
SNP: Single Nucleotide polymorphism; LocusName: Nearest Gene; rsID_LEAD_SNP: Rs ID number of the lead SNP;  CP: Chromosome/Position (build hg19/37); EA: Effect allele of 
the discovered SNP; EAF: Frequency of the effect allele; BETA_comb: Effect size in meta-analysis; SE_comb; Standard Error of the effect in meta-analysis; P_comb: Meta-analysis 
P-value; BETA_UKB: Effect size in UK Biobank analysis; SE_UKB: Standard Error of the effect in the UK Biobank analysis; P_UKB: UK Biobank analysis P-
value;BETA_AlcGenCHARGE+: Effect size in the AlcGen meta-analysis; SE_AlcGenCHARGE+: Standard Error of the effect in the AlcGen meta-analysis; P_AlcGenCHARGE+: AlcGen 
meta-analysis P-value 
 
FIGURE CAPTIONS 
Figure 1. Manhattan plot showing P-values from discovery genome-wide 
association meta-analysis with alcohol intake (log g/d) among 480,842 individuals 
across UK Biobank, AlcGen and CHARGE+, excluding known variants. The P-value 
was computed using inverse variance fixed effects models. The y axis shows the –
log10 P values and the x axis shows their chromosomal positions. Horizontal blue line 
represents the threshold of P = 5 x 10-9. 
 
Figure 2. Association of alcohol intake loci with other traits. Plot shows results from 
associations with other traits which were extracted from the PhenoScanner database 
for the 46 novel sentinel SNPs including proxies in Linkage Disequilibrium (r2 ≥ 0.8) 
with genome-wide significant associations. Each colored line connects a specific 
variant with the associated traits and diseases. 
 
Figure 3. Mediation effect of the grey matter volume of  bilateral putamen on the 
relationship between SNP rs13107325 and alcohol intake. The green is for left 
putamen, and, the red is for the right one.  We use ‘a’ for the relationship between 
rs13107325 and putamen, ‘b’ for the relationship between putamen and alcohol 
consumption, ‘c’ for the relationship between rs13107325 and alcohol consumption, 
‘c’’ for the relationship between rs13107325 and alcohol consumption after 
excluding the effect of putamen, and ‘ab’ as the mediation effect. The significance 
tests are based on the bootstrapping method (10,000 times). Z- statistics and the 
corresponding P values are provided in parentheses. The brain icon was created 
using Mango software, version 4.1 (http://ric.uthscsa.edu/mango/). 
 
Figure 4. Comparison of Zip8 alcohol phenotypes in Drosophila. Flies were exposed 
to 100/50 Ethanol/Air vapor for 30 min for exposure 1, and the time to 50% loss of 
righting was determined (ST-50, sedation time).  After recovery on food for 4 hours, 
flies were re-exposed to the same vapors, and the second ST-50 recorded (left side).  
The resulting increase in ST-50, i.e. tolerance, is shown on the right. In a) 
overexpressed human hZIP8 in ics-expressing cells flies are compared against 
controls whereas in b) knockdown of the fly ortholog dZip71B is compared against 
controls. In c) flies carrying two transposon insertions in the endogenous dZip71B 
gene are compared against controls. Significance levels: ***P <0.001, **P <0.01, *P 
<0.05. Exact P-values are presented in the text.  
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Supplementary Tables Summary File 
Supplementary Tables are presented in a single xls file (574kb) with 16 sheets. Each 
sheet includes one supplementary table. Sheets are numbered from ST1 to ST16. 
Legends of the supplementary tables are summarized below.  
 
Supplementary Tables Legends 
Supplementary Table 1: Descriptive summary statistics of study participants in UK 
Biobank. 
Supplementary Table 2: Descriptive statistics and alcohol consumption assessment for 
each study contributing to the AlcGen and CHARGE+ consortia. 
Supplementary Table 3: Genotyping and imputation characteristics of studies used in 
meta-analysis. 
Supplementary Table 4: Heterogeneity metrics (Cochran's Q P-value and I^2) for the 
novel variants. 
Supplementary Table 5: Association results of 8 alcohol variants identified through 
the meta-analysis of UK Biobank and AlcGen with 5x10-9<P<5x10-8 . Results are 
ordered by P-value of combined analysis. 
Supplementry Table 6: Reporting of genome-wide significant associations (P<5E-08] 
of alcohol related SNPs with other diseases and traits  using Phenoscanner. 
Supplementary Table 7: Association results of 7 known alcohol variants identified 
through the meta-analysis of UK Biobank, AlcGen and CHARGE+.  Results are 
ordered by P-value. 
Supplementary Table 8: Sex adjusted mean of alcohol intake level (g/d) across  
quintiles of the GRS distribution in Airwave cohort. 
Supplementary Table 9: Associations of novel variants with MRI of brain (N=9,702). 
Supplementary Table 10: Mediation analysis results for volume of grey matter in 
putamen (left and right) on the relationship of SNP rs13107325 with alcohol. 
Supplementary table 11: Associations between Cardiac Magnetic Resonance 
measures and alcohol consumption-related SNPs (Ν = 10,706). 
Supplementary table 12: Associations between Liver fat measures and alcohol 
consumption-related SNPs (Ν=8,479). 
Supplementary Table 13: eQTL analysis results on 53 SNPs associated with alcohol 
consumption using the Genotype-Tissue Expression dataset (GTEx). 
Supplementary Table 14: eQTL analysis results on 53 SNPs associated with alcohol 
consumption that affected gene expression in the brain, using the dataset from the UK 
Brain Expression Consortium (UKBEC). 
Supplementary Table 15: Significant genes at P < 5e-09 from the gene-based analysis. 
Supplementary Table 16:  Genetic correlations between alcohol and traits with FDR 
significant association. The Bonferroni threshold is 2.1x10-4. Results are ordered by 
P-value. 
 
